Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | MMP13 | P45452 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ANPEP | P15144 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15831224 | 0.87 | ALDH1A1 (0.65) | ALDH1A1HTTSMN1; SMN2MMP13LMNA | |
| SCHEMBL2747972 | 0.85 | MAPK14 (0.57) | ALDH1A1HTTSMN1; SMN2MMP13POLB | |
| SCHEMBL12884472 | 0.83 | ALDH1A1 (0.62) | ALDH1A1HTTSMN1; SMN2MMP13LMNA | |
| SCHEMBL14229597 | 0.83 | ALDH1A1 (0.61) | ALDH1A1HTTSMN1; SMN2MMP13LMNA | |
| SCHEMBL9781382 | 0.83 | ALDH1A1 (0.64) | ALDH1A1HTTSMN1; SMN2MMP13LMNA | |
| SCHEMBL3815151 | 0.83 | ALDH1A1 (0.72) | ALDH1A1HTTSMN1; SMN2MMP13LMNA | |
| SCHEMBL2747621 | 0.82 | LMNA (0.53) | LMNAHPGDPOLBKDM4EMEN1 | |
| SCHEMBL2750482 | 0.82 | APEX1 (0.54) | ALDH1A1LMNAKMT2AAPEX1 | |
| SCHEMBL2750089 | 0.82 | ANPEP (0.53) | ALDH1A1POLBANPEPEPHX2 | |
| SCHEMBL23309902 | 0.82 | ALDH1A1 (0.59) | ALDH1A1HTTSMN1; SMN2MMP13LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178668-B2 | 2-aminopyridine kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | ERBB2, ABL2, TIE1 | ALDH1A1 945/4885HTT 2661/4885SMN1; SMN2 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.